Company profile: Accutar Bio
1.1 - Company Overview
Company description
- Provider of AI-driven drug discovery solutions, including ChemiRise for end-to-end retrosynthesis via a graph convolutional one-step reaction proposer; Chemi-Net for ADME prediction; targeted protein degradation (ER degraders for breast cancer, AR degraders for prostate cancer); an orbital docking platform from SMILES with conformational error detection; virtual screening validated by crystallization; and an AI platform for novel small molecule discovery for chronic inflammatory diseases.
Products and services
- AI-empowered Drug Discovery Platform: AI-driven platform accelerates discovery and development of novel small molecule drug candidates, particularly for chronic inflammatory diseases
- Targeted Protein Degradation: Mechanism-based platform architects drugs that degrade specific proteins, including ER degraders for breast cancer and AR degraders for prostate cancer
- Orbital Docking Platform: SMILES-based platform docks ligands from SMILES input and identifies conformational errors in high-resolution crystal structures
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Accutar Bio
Owkin
HQ: United States
Website
- Description: Provider of AI precision medicine solutions to discover and develop cancer treatments. Offerings include MSIntuit CRC for MSI pre-screening in colorectal cancer, DrugMATCH for drug repositioning, TargetMATCH for target and subgroup discovery, Substra federated learning software, the MOSAIC oncology multiomics dataset, and AI diagnostics for pathology images. Uses AI to identify drug candidates and de-risk and accelerate clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Owkin company profile →
Genial Genetics
HQ: United Kingdom
Website
- Description: Provider of health care equipment and services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genial Genetics company profile →
ClearLight Biotechnologies
HQ: United States
Website
- Description: Provider of CLARITY tissue clearing kits for lipid clearing of soft tissues (versions for high or low lipid content), 3D IHC consulting services for CLARITY tissue clearing and 3D immunohistochemistry, an immunostaining buffer optimized for tissues cleared with CLARITY, and Tru3D AI software service for 3D spatial biology to solve quantitative research problems.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ClearLight Biotechnologies company profile →
Protein Mechanics
HQ: United States
Website
- Description: Provider of cross-disciplinary computational techniques to accelerate drug discovery and design, offering novel methods that enable physically accurate modeling of biomolecular systems at unprecedented speeds, with the aim of making in silico biology an everyday tool for medical researchers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Protein Mechanics company profile →
LabCentral
HQ: United States
Website
- Description: Provider of a facility (LabCentral 238) offering on-site capacities for collaborative cell therapy programs in regenerative medicine and immuno-oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LabCentral company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Accutar Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Accutar Bio
2.2 - Growth funds investing in similar companies to Accutar Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Accutar Bio
4.2 - Public trading comparable groups for Accutar Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →